2011, Number 2
<< Back Next >>
Bol Med Hosp Infant Mex 2011; 68 (2)
Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines
Bottazzi ME, Dumonteil E, Valenzuela JG, Betancourt-Cravioto M, Tapia-Conyer R, Hotez PJ
Language: English
References: 49
Page: 138-146
PDF size: 363.98 Kb.
ABSTRACT
The neglected tropical diseases (NTDs) represent a group of chronic parasitic and related infections that promote poverty because of their impact on child development, pregnancy, and worker productivity. The estimated 20 million Mexicans who live below the poverty line suffer disproportionately from a high prevalence of neglected tropical diseases such as amebiasis, Chagas disease, dengue, leishmaniasis, soil-transmitted helminth infections, trachoma, and vivax malaria. However, because the NTDs occur predominantly among the poor, new industrial and financial models are required to establish innovative technologies to address these conditions in Mexico and elsewhere in Latin America. In response, the
Slim Initiative for Antipoverty Vaccine Development was established to foster a public/private partnership between key academic, government, and industrial institutions in the U.S. and Mexico. Initial emphasis will be placed on developing new vaccines for Chagas disease and leishmaniasis, two of the highest burden NTDs in Mexico and Mesoamerica.
REFERENCES
Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008;2:e300.
Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through neglected tropical disease control. Lancet 2009;373:1570-1575.
International Human Development Indicators. Mexico. Available at: http://hdrstats.undp.org/en/countries/profiles/MEX.html (accessed December 31, 2010).
The World Bank. Mexico. Available at: http://data.worldbank.org/country/mexico (accessed January 5, 2011).
The World Bank. Poverty gap. Available at: http://data.worldbank.org/indicator/SI.POV.GAP2 (accessed January 5, 2011).
Hotez PJ. Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and their Impact on Global Health and Development. Washington DC: ASM Press; 2008. p. 218.
De Silva N, Brooker S, Hotez P, Montresor A, Engels D, Savioli L. Soil transmitted helminth infections: updating the global picture. Trends Parasitol 2003;19:547-551.
Bleakley H. Disease and development: evidence from hookworm eradication in the American South. Q J Econ 2007;122:73-117.
World Health Organization. World Malaria Report 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241564106_eng.pdf
Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 yearsa review. Mem Inst Oswaldo Cruz 2006;101:345-354.
Gómez-Dantés H, Willoquet JR. Dengue in the Americas: challenges for prevention and control. Cad Saude Publica 2009;25(suppl 1):S19-S31.
Brunkard JM, Robles López JL, Ramirez J, Cifuentes E, Rothenberg SJ, Hunsperger EA, et al. Dengue fever seroprevalence and risk factors, Texas-Mexico border, 2004. Emerg Infect Dis 2007;13:1477-1483.
Bottazzi ME, Brown AS. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Expert Rev Vaccines 2008;7:1481-1492.
Hotez PJ, Ferris M. The antipoverty vaccines. Vaccine 2006;24:5787-5799.
Bottazzi ME, Miles AP, Diemert D, Hotez PJ. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines 2006;5:189-198.
Dumonteil E. Update on Chagas' disease in Mexico. Salud Publica Mex 1999;41:322-327.
Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006;22:552-557.
Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008;2:e313.
Flisser A, Velasco-Villa A, Martínez-Campos C, González-Domínguez F, Briseno-García B, García-Suárez R, et al. Infectious diseases in Mexico. A survey from 1995-2000. Arch Med Res 2002;33:343-350.
Velasco-Castrejón O, Valdespino JL, Tapia Conyer R, Salvatierra B, Guzmán Bracho C, Magos C, et al. Seroepidemiologia de la enfermedad de Chagas en Mexico. Salud Publica Mex 1992;34:186-196.
Guzmán-Bracho C, García-García L, Floriani-Verdugo J, Guerrero-Martínez S, Torres-Cosme M, Ramírez-Melgar C, et al. Riesgo de transmisión de Trypanosoma cruzi por transfusión de sangre en México. Rev Panam Salud Publica 1998;4:94-99.
Ramsey J, Ordonez R, Tello-López A, Phols JL, Sanchez V, Peterson AT. Actualidades sobre la epidemiología de la enfermedad de Chagas en México. In: Ramsey J, Tello-López A, Pohls JL, eds. Iniciativa para la Vigilancia y el Control de la Enfermedad de Chagas en la República Mexicana. Cuernavaca, Morelos: Instituto Nacional de Salud Pública; 2003. pp. 85-103.
Ibarra-Cerdeña CN, Sánchez-Cordero V, Townsend Peterson A, Ramsey JM. Ecology of North American Triatominae. Acta Trop 2009;110:178-186.
Bargues M D, Klisiowicz DR, González-Candelas F, Ramsey J, Monroy C, Ponce C, et al. Phylogeography and genetic variations of Triatoma dimidiata, the main Chagas disease vector in Central America, and its position within the genus Triatoma. PLoS Negl Trop Dis 2008;2:e233.
Dorn PL, Calderón C, Melgar S, Moguel B, Solórzano E, Dumonteil E, et al. Two distinct Triatoma dimidiata (Latreille, 1811) taxa are found in sympatry in Guatemala and Mexico. PLoS Negl Trop Dis 2009;3:e393.
Schmunis GA, Zicker F, Cruz JR, Cuchi P. Safety of blood supply for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg 2001;65:924-930.
Andrade-Narváez FJ, Vargas-González A, Canto-Lara SB, Damián-Centeno AG. Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Mem Inst Oswaldo Cruz 2001;96:163-167.
Velasco O, Savarino SJ, Walton BC, Gam AA, Neva FA. Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg 1989;41:280-288.
Monroy-Ostria A, Hernandez-Montes O, Barker DC. Aetiology of visceral leishmaniasis in Mexico. Acta Trop 2000;75:155-161.
Canto-Lara SB, Cardenas-Maruffo MF, Vargas-González A, Andrade-Narváez F. Isozyme characterization of Leishmania isolated from human cases with localized cutaneous leishmaniasis from the state of Campeche, Yucatan Peninsula, Mexico. Am J Trop Med Hyg 1998;58:444-447.
Canto-Lara SB, Van Wynsberghe NR, Vargas-González A, Ojeda-Farfán FF, Andrade-Narváez FJ. Use of monoclonal antibodies for the identification of Leishmania spp. isolated from humans and wild rodents in the State of Campeche, Mexico. Mem Inst Oswaldo Cruz 1999;94:305-309.
Hernandez-Montes O, Monroy-Ostria A, McCann S, Barker DC. Identification of Mexican Leishmania species by analysis of PCR amplified DNA. Acta Trop 1998;71:139-153.
Rebollar-Téllez EA, Ramírez-Fraire A, Andrade-Narváez FJ. A two years study on vectors of cutaneous leishmaniasis. Evidence for sylvatic transmission cycle in the state of Campeche, Mexico. Mem Inst Oswaldo Cruz 1996;91:555-560.
Pech-May A, Escobedo-Ortegón FJ, Berzunza-Cruz M, Rebollar-Téllez EA. Incrimination of four sandfly species previously unrecognized as vectors of Leishmania parasites in Mexico. Med Vet Entomol 2010;24:150-161.
Ibáñez-Bernal S, Rodríguez-Domínguez G, Gómez-Hernández CH, Ricardez-Esquinca JR. First record of Lutzomyia evansi (Nuñez-Tovar 1924) in Mexico (Diptera: Psychodidae, Phlebotominae). Mem Inst Oswaldo Cruz 2004;99:127-129.
Sachs JD. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health to the World Health Organization. Newton, MA, USA: Digital Design Group; 2001. Available at:http://www.cid.harvard.edu/archive/cmh/cmhreport.pdf
Mahoney RT, Morel CM. A Global Health Innovation System (GHIS). Innovation Strategy Today 2006;2:1-12.
Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005;309:401-404.
Sabin Vaccine Institute. Available at: http://www.sabin.org/(accessed January 3, 2011).
Hotez PJ, Brown AS. Neglected tropical disease vaccines. Biologicals 2009;37:160-164.
Burke MA, de Francisco A, Matlin SA. Monitoring the Financial Flows of Health Research 2007: Behind the Global Numbers. Geneva: Global Forum for Health Research; 2008.
The Commission on the Future of Vaccines in Latin America. Strengthening vaccination policies in Latin America. México D.F., México: Instituto Carso de la Salud, A.C., Fundación Carlos Slim; 2008.
San Diego Dialogue, a division of University of California San Diego Extension. Borderless Biotech & Mexico’s Emerging Life Sciences Industry. 2007. Available at: http://www.sandiegodialogue.org/pdfs/Borderless_Biotech.pdf
Possani LD. The past, present, and future of biotechnology in Mexico. Nat Biotech 2003;21:582-583.
Instituto Carlos Slim de la Salud. Informe 2009. Mexico: 2010. Available at: http://www.carlosslim.com/pdf/icss_informe2009.pdf
Loukas A, Bethony J, Brooker S, Hotez P. Hookworm vaccines: past, present, and future. Lancet Infect Dis 2006;6:733-741.
Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010;8:814-826.
Taylor K, Nguyen A, Stephenne J. The need for new vaccines. Vaccine 2009;27(suppl 6):G3-G8.
Secretaría de Salud. Informes de Morbilidad 2010. Sistema Nacional de Vigilancia Epidemiológica. México D.F., 2010. Available at: http://www.dgepi.salud.gob.mx/anuario/html/anuarios.html